Statement: the primary trial and the secondary trial both use subcutaneous injections as the route of administration for their interventions.
Primary_evidence: INTERVENTION 1:    Standard Chemotherapy   Patients receive cyclophosphamide-containing chemotherapy alone.   cyclophosphamide: Part of planned chemotherapy regimen INTERVENTION 2:    Chemotherapy Plus Goserelin   Patients receive goserelin subcutaneously once every 4 weeks beginning 1 week before start of cyclophosphamide-containing chemotherapy. Treatment continues until completion of chemotherapy in the absence of disease progression or unacceptable toxicity.   cyclophosphamide: Part of planned chemotherapy regimen   goserelin acetate: Given subcutaneously
Secondary_evidence: INTERVENTION 1:    PD-0332991 100 mg: Dose Escalation Cohort   In Phase 1-Part 1, participants received single oral dose of PD-0332991 100 mg capsule in lead-in period (7 days prior to Cycle 1 Day 1), followed by PD-0332991 100 mg capsule orally once daily continuously for 21 days followed by 7 days off treatment in each cycle of 28 days, unless participants experienced disease progression or unacceptable toxicity or withdrew consent. INTERVENTION 2:    PD-0332991 125 mg: Dose Escalation Cohort   In Phase 1-Part 1, participants received single oral dose of PD-0332991 125 mg capsule in lead-in period (7 days prior to Cycle 1 Day 1), followed by PD-0332991 125 mg capsule orally once daily continuously for 21 days followed by 7 days off treatment in each cycle of 28 days, unless participants experienced disease progression or unacceptable toxicity or withdrew consent.